根据名称进行药物检索

Adderall XR 与 Haloperidol Oral Solution, Concentrate

Adderall XR 与 Haloperidol Oral Solution, Concentrate互相作用以及同时服用的可能性。

检测结果:

Adderall XR <> Haloperidol Oral Solution, Concentrate

现实性: 22.12.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

问问你的医生之前使用氟哌啶醇一起苯丙胺。使用这些药物在一起可以使苯丙胺不太有效。如果你的医生开的这些药物在一起，可能需要的剂量调整或特别的测试安全地使用这些药物在一起。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

一般避免：苯丁酮抗精神病药可能拮抗药理作用的苯丙胺、苯丙胺衍生物，以及其他的中心作用感神经剂(即中枢神经系统兴奋剂). 相反，这些药物可以减少抗精神病药物的疗效丁酰苯类. 的确切机制的相互作用是未知的，但可能涉及相对影响，对多巴胺能的活动。几个临床研究已经表明，减少或缺乏效果的安非他明在肥胖精神病患者的治疗与氟哌啶醇和其他的神经抑制剂，最显着的是氯丙嗪. 在这些研究、右旋苯丙胺也不影响睡觉模式。另一项研究发现了氟哌啶醇抑制安非他明诱发的症状和可用于苯丙胺中毒。作为对反的相互作用，它是不确定是否中枢神经系统兴奋剂实际上是对抗的精神抑制效果丁酰苯类，由于中枢神经系统兴奋剂的单独已报告导致或加剧的先前存在的精神病症状。也有报告的急性肌张力障碍存在于两个正常、健康的年轻妇女给予氟哌啶醇和右旋苯丙胺的一部分neuropharmacological研究。提交人假定的反应是由于一个增强的多巴胺释放。

管理：苯丙胺、苯丙胺衍生物，以及其他的中枢神经系统兴奋剂通常不应该被用，特别是对于重量的减少，在患者与苯丁酮神经抑制剂。

来源

"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.
Marshall RD, Douglas CJ "Phenylpropanolamine-induced psychosis: potential predisposing factors." Gen Hosp Psychiatry 16 (1994): 358-60
Wharton BK "Nasal decongestants and paranoid psychosis." Br J Psychiatry 117 (1970): 439-40
Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4
Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392
Reid AA "Pharmacological antagonism between chlorpromazine and phenmetrazine in mental hospital patients." Med J Aust 1 (1964): 187-8
Finton CK, Barton M, Chernow B "Possible adverse effects of phenylpropanolamine (diet pills) on sympathetic nervous system function--caveat emptor!" Mil Med 147 (1982): 1072
Angrist B, Lee HK, Gershon S "The antagonism of amphetamine-induced symptomatology by a neuroleptic." Am J Psychiatry 131 (1974): 817-9
Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM "Combined drug therapy of chronic schizophrenics." Am J Psychiatry 177 (1961): 997
Cornelius JR, Soloff PH, Reynolds CF, 3d "Paranoia, homicidal behavior, and seizures associated with phenylpropanolamine." Am J Psychiatry 141 (1984): 120-1
Grieger TA, Clayton AH, Goyer PF "Affective disorder following use of phenylpropanolamine" Am J Psychiatry 147 (1990): 367-8
Capstick C, Checkley S, Gray J, Dawe S "Dystonia induced by amphetamine and haloperidol." Br J Psychiatry 165 (1994): 276
Lake CR, Tenglin R, Chernow B, Holloway HC "Psychomotor stimulant-induced mania in a genetically predisposed patient: a review of the literature and report of a case." J Clin Psychopharmacol 3 (1983): 97-100
Dietz AJ, Jr "Amphetamine-like reactions to phenylpropanolamine." JAMA 245 (1981): 601-2
Mueller SM "Neurologic complications of phenylpropanolamine use." Neurology 33 (1983): 650-2
Norvenius G, Widerlov E, Lonnerholm G "Phenylpropanolamine and mental disturbances" Lancet 2 (1979): 1367-8
Sletten IW, Ognjanov V, Menendez S, Sundland D, El-Toumi A "Weight reduction with chlorphentermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy." Curr Ther Res Clin Exp 9 (1967): 570-5
Lambert MT "Paranoid psychoses after abuse of proprietary cold remedies." Br J Psychiatry 151: (1987): 548-50
Modell W, Hussar AE "Failure of dextroamphetamine sulfate to incluence eating and sleeping patterns in obese schizophrenic patients." JAMA 193 (1965): 275-8
Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995): 457-8
"Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
Schaffer CB, Pauli MW "Psychotic reaction caused by proprietary oral diet agents." Am J Psychiatry 137 (1980): 1256-7
Dewsnap P, Libby G "A case of affective psychosis after routine use of proprietary cold remedy containing phenylpropanolamine" Hum Exp Toxicol 11 (1992): 295-6